JPRN-jRCT2080220313
Unknown
Phase 3
Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasis
ConditionsPsoriasis
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Psoriasis
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\[Inclusion criteria]
- •Psoriasis patients who are candidates for phototherapy or systemic therapy, 16 years and above, male and female.
- •\[Exclusion criteria]
- •Patients who, have previously used any anti\-TNFalpha therapy, have a history of serious infection which caused hospitalization within 6 months before the registration, have an active tuberculosis, have a complication or a history of malignancy within 5 years before the registration.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
result of vitimelin tablet and vitimelin oil in vitiligoHealth Condition 1: L80- VitiligoCTRI/2021/04/033014DrVasishths Ayuremedies30
Completed
Phase 2
A study for Under eye dark circlesCTRI/2022/09/045732Transformative Learning Solutions Pvt Ltd32
Active, Not Recruiting
N/A
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AEUCTR2005-003552-35-DEOctapharma AG116
Completed
Phase 2
Clinical study on Dabur gel in reduction of oral malodor.Health Condition 1: R196- HalitosisCTRI/2021/07/034750Dabur India limited161
Active, Not Recruiting
N/A
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AIdiopathic thrombocytopenic purpura, in adults actively bleeding or at high risk bleeding.MedDRA version: 7.0Level: LLTClassification code 10021245EUCTR2005-003552-35-ATOctapharma AG116